Explore our tests
20 Years of Genomics Experience
We spun off from the Indian Institute of Science. We created the first College of American Pathologists-accredited laboratory for Genomic Sequencing in India. We have contributed to ~25000 peer-reviewed scientific publications that push the frontiers of genomics research. The bioinformatics platforms and the medical literature curation capabilities that power our tests are tried and tested, not only by us but by many leading global genomics companies
Oncology Treatment Selection
There are ~55 genomic biomarkers that influence Standard of Care therapeutic decision-making. In addition, there are ~120 genomic biomarkers that influence therapy choice on an experimental basis. Our tests cover all the above, both from tissue and from liquid biopsies. Our reporting is driven by decade long investment in curating medical literature per the Association of Molecular Pathology Guidelines. Here is a publication showing the extensive validation our tests goes through.
Cancer Risk
~10% of all breast and ovarian cancers globally and a fraction of colorectal, prostate and pancreatic cancers occur on account of inherited mutations. Our pioneering publication shows this fraction is at least as high if not substantially higher in India.
Comprehensive Gene Coverage
Our test covers all genes clinically proven to carry inherited risk for Breast, Ovarian, Prostate, Pancreatic, Colorectal and Hematological cancers
Detailed Variant Analysis
We carefully handle all the variant complexity: confounding base calls, pseudogenes, copy number variants etc
Accurate Variant Classification
Our variant classifications per the American College of Medical Pathologist guidelines are based on a decade of investment in automation and medical literature curation
Rare Diseases and Reproductive Health
Our Exome and Low Pass Whole Genome tests along with supporting Sanger/MLPA tests provide a comprehensive solution to the diagnosis of ~5000 Mendelian diseases. Our tests ensure accurate calling of Single Nucleotide Variants, Insertions, and Deletions, as well as Multi-exon and some single-exon Deletions & Duplications to achieve industry-leading diagnostic rates.
In a cohort of >1000 Pediatric Neurology cases, 12% of the variants called by our test were copy number variants that are otherwise hard to identify (see publication)
Our Exome provides >100x coverage on >95% of the bases in genes associated with ~5000 mendelian disorders
Our bioinformatics platforms carry more than a decade of investment in the latest algorithms and curation of medical literature, and are used globally
Our team of over 50 bioinformaticians and medical genetics specialists reviews each variant carefully to handle the many complex issues that can stand between the right diagnosis and a wrong one
GenomicWellness
For healthy adults who are curious about their genomes: get your genome sequenced and keep in touch with the scientific progress that is happening at a breakneck pace to manage any genomic risks to your health.
Genomic Health Insights
For those who are curious about their genome: get your genes sequenced and keep in touch with scientific progress that can help manage any genomic risks to your health. We will sequence all ~20,000 genes and you will receive your results on a secure portal comprising risk reports for various diseases, carrier status for mutations that might affect your children, as well as genetic predispositions to commonly used drugs.
Breast Assure - Strand's HBOC Test
Hereditary Breast and Ovarian Cancer syndrome (HBOC) is a genetic condition that makes it more likely that a person will get breast, ovarian, and other cancers.
HBOC is hereditary, meaning that it is caused by a mutation (genetic change) that can be passed down in families. A genetic test can help determine if your personal or family history of cancer was caused by HBOC. If you are found to have HBOC, there are interventions that can help prevent cancer or detect it early.
Bioinformatics & Variant Interpretation
Genome sequencing on a single sample yields 10-100 Gigabytes of data; it’s easy to miss the important bits unless ones analytical platforms are robust and thorough. Our proprietary platforms below have been built entirely from scratch and have matured over a decade of clinical use.
Strand NGS
Strand NGS processes GBs of data automatically to convert raw sequencing output to genomics variants. Over 800 global publications and industry leading visualization attest to its robustness
Strand Omics
With streamlined workflows, powerful filtering, extensive curated content, and detailed audit logs, Strand Omics enables reliable identification of the one or two key genomic variants from the tens to hundreds of thousands found for each sample in inherited diseases cases.
Strand Iris
With its extensive database of 30,000 variants in 600 genes, ~750 drug associations, 80,000 clinical trials and an extensive rules engine, Strand Iris enables robust and automated identification of appropriate cancer treatment
Covid-19 Genomic Surveillance
Strand is part of the INSACOG consortium and worked closely with philanthrophic partners and the Bangalore municipality to monitor the evolution of SARS-CoV-2 strains in and around Bangalore.
Strand Testing Process
Pre-test session
1
Sample Collection
2
Logistics
3
Lab Processing
4
Bioinformatics
5
Reports Signout
6
Post-test session
7
Trusted by Global Companies
What Our Customers Say
View All
Event
Media
Publications
View All
25 October, 2024
Integrating Genomic Testing for Cancer in Gyn...
Join us for an insightful webinar on “Integrating Genomic Testing in Gynecol...
18 January, 2024
Personalized & Meaningful Genomics...
Join our webinar – ‘Personalized & Meaningful Genomics: A Genetic ...
17 December, 2023
HBOC Beyond BRCA...
Join us for an insightful discussion on “HBOC Beyond BRCA: The Clinical Util...
25 November, 2023
Role of Liquid Biopsy in NSCLC...
4th Strand Connect International Panel Discussion on Role of Liquid Biopsy in NSCL...
View All
Clinician
Patient